27258-33-9

Basic information

• Product Name: 1-Methyl-1H-pyrazole-5-carbaldehyde
• Synonyms: ART-CHEM-BB B007393;ASINEX-REAG BAS 10156687;(1-METHYL-1H-PYRAZOLE-5-CARBALDEHYDE);2-METHYL-2H-PYRAZOLE-3-CARBALDEHYDE;AKOS B007393;5-FORMYL-1-METHYL-1H-PYRAZOLE;1-Methyl-1H-pyrazole-5-carboxaldehyde;1-Methyl-1H-pyrazole-5-carboxaldehyde 97%
• CAS NO: 27258-33-9
• Molecular Formula: C₅H₆N₂O
• Molecular Weight: 110.11
• Product Categories: Aldehyde;Building Blocks;Pyrazole
• Mol File: 27258-33-9.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 115/15mm
• Flash Point: 66℃
• Appearance: /
• Density: 1.118 g/mL at 25 °C
• Vapor Pressure: 0.123mmHg at 25°C
• Refractive Index: n20/D1.521
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 0.56±0.10(Predicted)
• CAS DataBase Reference: 1-Methyl-1H-pyrazole-5-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-1H-pyrazole-5-carbaldehyde(27258-33-9)
• EPA Substance Registry System: 1-Methyl-1H-pyrazole-5-carbaldehyde(27258-33-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 27258-33-9(Hazardous Substances Data)

Usage

General Description

1-Methyl-1H-pyrazole-5-carbaldehyde is a chemical compound with the molecular formula C6H6N2O. It is a pyrazole derivative and an aldehyde, which means it contains a carbonyl group. 1-Methyl-1H-pyrazole-5-carbaldehyde is used in organic synthesis as a building block for the preparation of various pharmaceutical and agrochemical compounds. Its aldehyde group makes it a versatile intermediate for the synthesis of heterocyclic compounds, which are widely used in medicinal chemistry. Additionally, 1-Methyl-1H-pyrazole-5-carbaldehyde has potential applications in the field of materials science, particularly in the development of new functionalized materials and polymers. Overall, this chemical compound has diverse uses in the fields of chemistry, pharmacology, and materials science due to its unique structure and reactivity.

InChI:InChI=1/C5H6N2O/c1-7-5(4-8)2-3-6-7/h2-4H,1H3

Upstream product

• 1269291-90-8 5-(dimethoxymethyl)-1-methyl-1H-pyrazole 
• 930-36-9 1-methyl-1H-pyrazole 
• 68-12-2 N,N-dimethyl-formamide 
• 616-47-7 1-methyl-1H-imidazole 
• 67751-23-9 4-(dimethylamino)-1,1-dimethoxy-but-3-en-2-one 
• 60-34-4 methylhydrazine 

Downstream Products

• 313753-40-1 methyl 7-{4-[2-(butoxy)ethoxy]phenyl}-1-[(1-methyl-1H-pyrazol-5-yl)methyl]-2,3-dihydro-1H-1-benzazepine-4-carboxylate 
• 473528-88-0 4-bromo-1-methyl-1H-pyrazole-5-carboxaldehyde 
• 1276056-83-7 (4-bromo-1-methyl-1H-pyrazol-5-yl)methanol 
• 796845-50-6 3-(1-methyl-1H-pyrazol-5-yl)propanoic acid 
• 874278-23-6 C₂₆H₃₂N₆ 
• 148408-72-4 (R)-(+)-1-Methyl-α-phenyl-1H-pyrazole-5-methanol 
• 497852-78-5 7-{4-[2-(butoxy)ethoxy]phenyl}-1-isobutyl-N-({4-[(1-methyl-1H-pyrazol-5-yl)methyl]sulfanyl}phenyl)-2,3-dihydro-1H-1-benzazepine-4-carboxamide 
• 497855-73-9 4-{[(1-methyl-1H-pyrazol-5-yl)methyl]sulfanyl}aniline 
• 84547-61-5 (1-methyl-1H-pyrazol-5-yl)methanol 

Relevant articles and documents

MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Preparation method of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)ethanamine

The invention relates to a preparation method of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)ethanamine. The method comprises the following steps: reacting 1-methylpyrazole used as a raw material to obtain 1-methyl-1H-pyrazole-5-carbaldehyde; adding piperidine and pyridine to obtain a solid 3-(1-methyl-1H-pyrazole-5-yl) acrylic acid; further, adding palladium on carbon into a methanol solution, and introducing hydrogen to obtain 3-(1-methyl-1H-pyrazol-5-yl) propionic acid; furthermore, reacting under roles of bromine and saturated sodium sulphite solution, and performing spinning drying to obtain a solid 3-(4-bromo-1-methyl-1H-pyrazol-5-yl) propionic acid; adding thionyl chloride, tetrahydrofuran, and stronger ammonia water, reacting, dissolving out methyl alcohol, purifying silica gel, eluting ethyl acetate in sequence to obtain 3-(4-bromo-1-methyl-1H-pyrazol-5-yl) propanamide; finally adding NaOH and bromine, and performing ice-bath to obtain 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)ethanamine. The method has the advantages of being clear in steps, little in waste, high in yield, easy to operate and capable of saving raw materials.

Spin transition in the molecular heterospin complex of Cu(hfac)2 with 4,4,5,5-tetramethyl-2-(1-methylpyrazol-5-yl)-4,5-dihydroimidazole-1-oxyl 3-oxide

The synthesis, structure, and magnetic properties of the products of the reaction for Cu(hfac)2 (hfac is hexafluoroacetylacetonate) with spin-labeled nitronyl nitroxides 4,4,5,5-tetramethyl-2-(1-R-1H-pyrazol-5-yl)-3- imidazoline-1-oxyl 3-oxides L5/R (R = Me, Et, Pr, Bu), viz., binuclear complex [Cu(hfac)2L5/Me]2 and chain polymer complexes [Cu(hfac)2L5/R]n, are described. The polymer heterospin chains are built according to head-to-head (R = Me, Et, Pr, Bu) and head-to-tail (R = Pr, Bu) motifs. Compound [Cu(hfac)2L5/Me]2 is characterized by the ability to reveal the reversible effect of thermally induced spin transition at a temperature about 75 K (without hysteresis). In the set of heterospin CuII compounds with spin-labeled pyrazoles, this is the earlier unknown example of a molecular complex exhibiting a similar magnetic anomaly.